Needham & Company affirms Acadia Pharma (Nasdaq: ACAD) at Buy with a price target of $49 following Q2 results on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE